Erika Hamilton, MD

Erika Hamilton, MD, is the director of breast cancer research at Sarah Cannon Research Institute.

Articles by Erika Hamilton, MD

TROP2 ADC Shows Promise in Pretreated TNBC: Erika Hamilton, MD

December 8th 2025

Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in heavily pretreated TNBC patients.

Early Trial Data Show TROP2-Targeted ADC DB-1305/BNT325 Activity in TNBC: Erika Hamilton, MD

BySabrina McCrear,Erika Hamilton, MD

December 5th 2025

A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment.

Latest Updated Articles

Early Trial Data Show TROP2-Targeted ADC DB-1305/BNT325 Activity in TNBC: Erika Hamilton, MD
December 5th 2025

Erika Hamilton, MD

Articles by Erika Hamilton, MD

TROP2 ADC Shows Promise in Pretreated TNBC: Erika Hamilton, MD

Early Trial Data Show TROP2-Targeted ADC DB-1305/BNT325 Activity in TNBC: Erika Hamilton, MD

Latest Updated Articles

Trending on AJMC

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Erika Hamilton, MD

Articles by Erika Hamilton, MD

TROP2 ADC Shows Promise in Pretreated TNBC: Erika Hamilton, MD

Early Trial Data Show TROP2-Targeted ADC DB-1305/BNT325 Activity in TNBC: Erika Hamilton, MD

Latest Updated Articles

Trending on AJMC

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure